This study looks back at medical records from over 300 patients in France who received Glofitamab, a cancer treatment, through an expanded access program. Researchers want to understand how well this drug works and what side effects patients experienced in real-world conditions, rather than in a controlled study setting.
Key Objective:This research will provide real-world evidence about how effective and safe Glofitamab is for treating large B-cell lymphoma in everyday clinical practice.
Who to Consider:Patients with large B-cell lymphoma who have already received Glofitamab through the expanded access program in France and whose medical records can be reviewed for this retrospective analysis.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].
Eligibility Criteria
Inclusion Criteria: * patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024 * patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab * adult patient * patient who is informed of the study and who did not oppose to their data collection Exclusion Criteria: * none